Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better

© 2025 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

Author Information

Peter J. Gawne¹,²,³,
Helen E. Bryant⁴,
Steven G. DuBois⁵,
Sally L. George⁶,⁷,
Juliet Gray⁸,
Leona Knox⁹,
Kyle B. Matchett¹⁰,
Connie Peet¹¹,
Katherine A. Vallis¹²,
Hugh J. Wallace¹³,¹⁴,¹⁵,
Simon Wan¹⁶ and
Mark N. Gaze¹⁷

¹Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary, University of London, London, United Kingdom;
²UCL Cancer Institute, University College London, London, United Kingdom;
³School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom;
⁴School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom;
⁵Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts;
⁶Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom;
⁷Children and Young People’s Unit, Royal Marsden Hospital, London, United Kingdom;
⁸Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom;
⁹Solving Kids’ Cancer, London, United Kingdom;
¹⁰Personalised Medicine Centre and Clinical Translational Research and Innovation Centre, Altnagelvin Area Hospital, School of Medicine, Ulster University, Derry-Londonderry, United Kingdom;
¹¹Department of Radiotherapy, University College London Hospitals NHS Foundation Trust, London, United Kingdom;
¹²Department of Oncology, University of Oxford, Oxford, United Kingdom;
¹³Paediatric Nuclear Medicine, Royal Hospital for Children, Glasgow, United Kingdom;
¹⁴Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom;
¹⁵University of Glasgow, Glasgow, United Kingdom;
¹⁶Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust/University College London, London, United Kingdom; and
¹⁷Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom